CORRECTING & REPLACING Munich Leukemia Laboratory Selects IBM Watson & Illumina for Research Collaboration to Advance Diagnos...
March 08 2017 - 3:52AM
Business Wire
Watson Takes on Hematology Research in First
Collaboration in Germany; Effort Marks Illumina’s First European
Adopter of NovaSeq™
Please replace the release with the following corrected version
due to multiple revisions.
The corrected release reads:
CORRECTING AND REPLACING MUNICH
LEUKEMIA LABORATORY SELECTS IBM WATSON AND ILLUMINA FOR RESEARCH
COLLABORATION TO ADVANCE DIAGNOSTICS AND DEVELOP PERSONALIZED
TREATMENT TOOLS FOR LEUKEMIA & LYMPHOMA
Watson Takes on Hematology Research in First
Collaboration in Germany; Effort Marks Illumina’s First European
Adopter of NovaSeq™
Munich Leukemia Laboratory (MLL), a state-of-the-art leukemia
and lymphoma diagnostic and research laboratory based in Munich,
has teamed up with IBM (NYSE: IBM) and Illumina, Inc. (NASDAQ:
ILMN) to help build a new cognitive technology prototype that aims
to help researchers improve leukemia treatment.
The prevalence of leukemia is on the rise in Europe, with 15,000
new diagnoses each year in Germany alone.(1) MLL will use NovaSeq
technology from Illumina, the global leader in next-generation
sequencing technology, to sequence samples from its biobank of more
than 500,000 cases. MLL researchers then plan to use Watson to help
interpret the genomic data alongside other data sources. The
project intends to include innovative testing processes such as
automated phenotyping and genotyping including whole genome
sequencing (WGS) and transcriptome sequencing (RNA-Seq) in 5,000
cases.
The ultimate goal is to develop a Watson-based technology
prototype that can analyze genomic and phenotypic data alongside
medical literature, guidelines and study results, providing
clinicians with information relevant to leukemia care. Following
successful development, the tool could also be made available to
other laboratories in the future.
Prof. Torsten Haferlach, co-founder and CEO of MLL, states, “We
at MLL are excited to combine our data and knowledge, IBM’s
cognitive computing tools, and Illumina’s new sequencing platform
to create a new era of insights in leukemia biology that will also
drive more personalized treatment strategies.”
“As a company committed to improving human health, we are
delighted to welcome MLL as our first European customer to adopt
the NovaSeq platform,” said Paula Dowdy, Senior Vice President and
General Manager, Illumina, Europe, Middle East, and Africa. “MLL’s
strategic decision to create a future path for whole-genome
sequencing to help promote better health outcomes, reflects one of
Illumina’s key strategies to connect genomics to the everyday lives
of those living with cancer.”
MLL will utilize Illumina’s BaseSpace Informatics Suite to be
able to streamline data analysis, storage, data curation and
aggregation. The BaseSpace Sequence Hub Frankfurt site will
help MLL manage the data as the project scales and facilitates data
transfer to IBM Watson. Additional tertiary analysis with BaseSpace
Cohort Analyzer and BaseSpace Correlation Engine allows MLL’s
genomic data to be combined with other clinical data to enhance
interpretation results.
“Cognitive computing is critical to help providers unlock the
insights hidden in large data pools and scale their expertise in a
global market through digital services,” said Bart de Witte,
director of digital health, IBM. “This research collaboration is
indicative of the growing global market to create and implement new
cognitive approaches to data-driven challenges for health systems
that are increasingly overwhelmed by data.”
Sources:
(1) European Leukemia Network:
https://www.leukemia-net.org/content/home/index_eng.html
About MLL
The Munich Leukemia Laboratory was founded in 2005 to take
diagnostic responsibility for patients with leukemia and lymphoma
for both in-patient and out-patient settings. The team of 150
hematologists, researchers and technicians works to optimize and
refine diagnostics, including automation of laboratory procedures
and improvements according to the established norms of EN ISO 15189
as well as national and international involvement in scientific
projects and research trials. MLL is committed to expanding and
improving high-quality diagnostics of hematological neoplasms, at
the highest scientific and technical levels.
About IBM
IBM Watson is the first commercially available cognitive
computing capability representing a new era in computing. The
system, delivered through the cloud, analyzes high volumes of data,
understands complex questions posed in natural language, and
proposes evidence-based answers. Watson continuously learns,
gaining in value and knowledge over time, from previous
interactions. The IBM Watson Health unit helps improve the ability
of doctors, researchers and insurers to innovate by surfacing
insights from the massive amount of personal health data being
created and shared daily. For more information on IBM Watson,
visit: ibm.com/watson. For more information on IBM Watson Health,
visit: ibm.com/watsonhealth.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170307006545/en/
MLL Media ContactTorsten Haferlach, +49 89
990170torsten.haferlach@mll.comorIBM Media ContactsIBM
DACHAnnette Fassnacht, +49 151
65136642annettefassnacht@de.ibm.comorIBM Watson HealthChristine
Douglasscgdouglass@us.ibm.comorIllumina, Inc.
ContactsInvestors:Rebecca Chambers,
858-255-5243ir@illumina.comorMedia:David Robertson, +44 1223
824909(Europe, Middle East, and Africa)orJen Carroll,
858-882-6822(US)pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024